KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short-term Investments (2020 - 2025)

Recursion Pharmaceuticals' Short-term Investments history spans 6 years, with the latest figure at $4.6 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 50.87% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, up 50.87%, while the annual FY2025 figure was $4.6 million, 50.87% up from the prior year.
  • Short-term Investments reached $4.6 million in Q4 2025 per RXRX's latest filing, up from $3.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $231.4 million in Q4 2021 to a low of $1.3 million in Q4 2022.
  • Average Short-term Investments over 5 years is $21.9 million, with a median of $3.2 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: surged 11472.3% in 2021, then plummeted 99.45% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $231.4 million in 2021, then tumbled by 99.45% to $1.3 million in 2022, then soared by 152.42% to $3.2 million in 2023, then decreased by 5.76% to $3.0 million in 2024, then skyrocketed by 50.87% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Short-term Investments are $4.6 million (Q4 2025), $3.1 million (Q3 2025), and $3.1 million (Q2 2025).